Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mona Shafey

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Leukemia & Lymphoma|September 21, 2011
Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphomaMona Shafey, Qiuli Duan, James Russell, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 7, 2024
Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP)Kevin Thai, Jennifer Jupp, Deonne Dersch-Mills, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
A Canadian Perspective on the Treatment of Waldenström MacroglobulinemiaRayan Kaedbey, Nicholas Forward, Laurie H Sehn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2019
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible PatientsSheilagh Sanders, Neil Chua, Jean-François Larouche, et al.
Transplantation and Cellular Therapy|September 13, 2023
Consolidative Autotransplantation Achieves High Cure Rates in Adverse-Risk Large B Cell LymphomaRobert Puckrin, Russell Sterrett, Neil Chua, et al.
Thrombosis and Haemostasis|March 30, 2007
Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysisMona Shafey, Josdalyne L Anderson, Dimitri Scarvelis, et al.
European Journal of Haematology|February 16, 2026
Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRebecca Tidswell, Carolyn Owen, Mona Shafey, et al.
Leukemia & Lymphoma|July 5, 2024
Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphomaColin Stewart, Carolyn Owen, Neil Chua, et al.
British Journal of Haematology|March 17, 2026
Limited diagnostic utility of bone marrow sampling in PET-defined limited-stage follicular lymphomaMarissa Solow, Carolyn Owen, Colin Stewart, et al.
Leukemia & Lymphoma|March 12, 2013
High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphomaArchana Vijay, Qiuli Duan, Jan-Willem Henning, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|September 21, 2011
Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphomaMona Shafey, Qiuli Duan, James Russell, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 7, 2024
Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP)Kevin Thai, Jennifer Jupp, Deonne Dersch-Mills, et al.
Current Oncology (Toronto, Ont.)|October 27, 2022
A Canadian Perspective on the Treatment of Waldenström MacroglobulinemiaRayan Kaedbey, Nicholas Forward, Laurie H Sehn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2019
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible PatientsSheilagh Sanders, Neil Chua, Jean-François Larouche, et al.
Transplantation and Cellular Therapy|September 13, 2023
Consolidative Autotransplantation Achieves High Cure Rates in Adverse-Risk Large B Cell LymphomaRobert Puckrin, Russell Sterrett, Neil Chua, et al.
Thrombosis and Haemostasis|March 30, 2007
Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysisMona Shafey, Josdalyne L Anderson, Dimitri Scarvelis, et al.
European Journal of Haematology|February 16, 2026
Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRebecca Tidswell, Carolyn Owen, Mona Shafey, et al.
Leukemia & Lymphoma|July 5, 2024
Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphomaColin Stewart, Carolyn Owen, Neil Chua, et al.
British Journal of Haematology|March 17, 2026
Limited diagnostic utility of bone marrow sampling in PET-defined limited-stage follicular lymphomaMarissa Solow, Carolyn Owen, Colin Stewart, et al.
Leukemia & Lymphoma|March 12, 2013
High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphomaArchana Vijay, Qiuli Duan, Jan-Willem Henning, et al.
Pageof 4